newsfilter
← Latest News
GlobeNewswire·

Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Preliminary data from the Phase 1b/2 study of TH103 in nAMD is now expected in the second half of 2027 due to a supply interruption
  • A new batch of TH103 material is expected in Q2 2027 after a pilot manufacturer batch failed aggregation specifications
  • Technology transfer from pilot to commercial-scale manufacturer KBI Biopharma was completed with test batches meeting target specifications
  • Potential initiation of a Phase 3 program is now expected in 2028
  • Cash, cash equivalents, & marketable securities totaled $82.9 million as of September 30, 2026, sufficient to fund operations into 2028
  • Research and development expenses were $8.3 million for the quarter ended September 30, 2026, down from $9.1 million in the prior year quarter
  • General and administrative expenses were $3.5 million for the quarter ended September 30, 2026, down from $3.6 million in the prior year quarter
  • Net loss for the quarter ended September 30, 2026, was $11.0 million compared to $11.9 million in the prior year quarter
  • The Phase 1b/2 study aims to assess safety & efficacy of up to four monthly loading doses of TH103 in approximately 60-80 nAMD patients
  • TH103 is an investigational dual-targeting biologic engineered by Dr. Napoleone Ferrara for intravitreal delivery in retinal diseases
Company
Kalaris Therapeutics, Inc.
Keywords
Nasdaq:KLRS, Kalaris Therapeutics, Inc.